RecruitingNCT06433817
Spectral CT in Radiotherapy for Cervical Cancer
The Clinical Research of Spectral CT in Radiotherapy for Cervical Cancer
Sponsor
Peking Union Medical College Hospital
Enrollment
150 participants
Start Date
May 22, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study was to explore the potential application of spectral CT for radiotherapy in cervical cancer.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria4
- All patients were confirmed cervical cancer by pathology
- patients were treated with concurrent chemoradiotherapy
- Spectral CT scans acquisition performed during the arterial phase and venous phase
- All the patients underwent a 18F-FDG PET/CT before treatment
Exclusion Criteria3
- CT without spectral scans
- History of allergy to intravenous contrast
- Pregnant or potentially pregnant female subjects
Interventions
RADIATIONSpectral computed tomography scan
Spectral CT scans acquisition performed during the arterial phase and venous phase for cervical cancer
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06433817
Related Trials
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
NCT059417413 locations
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
NCT049774538 locations
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180239 locations
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT0721670360 locations